Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CALT NASDAQ:CVAC NASDAQ:DVAX NASDAQ:TLMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCALTCalliditas Therapeutics AB (publ)$40.00$40.00$15.25▼$43.00$1.19B1.7710,339 shsN/ACVACCureVac$5.37$5.43$2.37▼$5.72$1.20B2.53636,357 shs321,215 shsDVAXDynavax Technologies$10.12-1.5%$10.62$9.22▼$14.63$1.19B1.241.87 million shs1.16 million shsTLMDSOC Telemed$3.00$2.98$0.55▼$8.00$302.52M-1.441.28 million shsN/AThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCALTCalliditas Therapeutics AB (publ)0.00%0.00%0.00%0.00%-1.23%CVACCureVac0.00%-1.29%-0.37%+18.54%+67.29%DVAXDynavax Technologies0.00%-3.62%-7.83%+3.16%-8.08%TLMDSOC Telemed0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCALTCalliditas Therapeutics AB (publ)N/AN/AN/AN/AN/AN/AN/AN/ACVACCureVac4.3469 of 5 stars3.15.00.04.92.80.01.3DVAXDynavax Technologies4.6578 of 5 stars3.32.00.04.73.53.31.9TLMDSOC TelemedN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCALTCalliditas Therapeutics AB (publ) 0.00N/AN/AN/ACVACCureVac 2.20Hold$6.8327.25% UpsideDVAXDynavax Technologies 2.50Moderate Buy$24.33140.45% UpsideTLMDSOC Telemed 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest TLMD, CVAC, DVAX, and CALT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/22/2025DVAXDynavax TechnologiesJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$32.008/8/2025DVAXDynavax TechnologiesJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Outperform ➝ Market Outperform$31.00 ➝ $32.006/26/2025CVACCureVacUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Neutral$12.00 ➝ $5.506/13/2025CVACCureVacJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$7.00 ➝ $5.006/12/2025CVACCureVacCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeMarket Perform6/12/2025CVACCureVacCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 8/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCALTCalliditas Therapeutics AB (publ)$1.60B0.74N/AN/A$1.06 per share37.74CVACCureVac$579.18M2.08$0.87 per share6.15$3.36 per share1.60DVAXDynavax Technologies$277.25M4.28$0.16 per share63.91$4.54 per share2.23TLMDSOC Telemed$94.44M3.20N/AN/A$1.66 per share1.81Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCALTCalliditas Therapeutics AB (publ)-$43.96M-$1.85N/A8.68N/A-30.18%-212.04%-27.96%N/ACVACCureVac$175.50M$0.965.59N/AN/A38.21%29.57%25.41%11/11/2025 (Estimated)DVAXDynavax Technologies$27.31M-$0.46N/A20.65N/A-16.67%5.10%3.00%11/6/2025 (Estimated)TLMDSOC Telemed-$50.54M-$0.57N/A∞N/A-53.52%-34.32%-20.96%N/ALatest TLMD, CVAC, DVAX, and CALT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/21/2025Q2 2025CVACCureVac-$0.15-$0.30-$0.15-$0.30$4.27 million$1.41 million8/7/2025Q2 2025DVAXDynavax Technologies$0.12$0.14+$0.02$0.14$87.55 million$95.44 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCALTCalliditas Therapeutics AB (publ)N/AN/AN/AN/AN/ACVACCureVacN/AN/AN/AN/AN/ADVAXDynavax TechnologiesN/AN/AN/AN/AN/ATLMDSOC TelemedN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCALTCalliditas Therapeutics AB (publ)9.442.692.59CVACCureVac0.056.176.16DVAXDynavax Technologies0.456.656.01TLMDSOC Telemed0.523.323.28Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCALTCalliditas Therapeutics AB (publ)2.83%CVACCureVac17.26%DVAXDynavax Technologies96.96%TLMDSOC TelemedN/AInsider OwnershipCompanyInsider OwnershipCALTCalliditas Therapeutics AB (publ)2.20%CVACCureVacN/ADVAXDynavax Technologies2.98%TLMDSOC Telemed6.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCALTCalliditas Therapeutics AB (publ)18029.79 million29.14 millionOptionableCVACCureVac880224.34 millionN/AOptionableDVAXDynavax Technologies350117.27 million113.77 millionOptionableTLMDSOC Telemed226100.84 million93.88 millionOptionableTLMD, CVAC, DVAX, and CALT HeadlinesRecent News About These CompaniesThe Woman’s World Expert-Reviewed Glossary of GLP-1, Semaglutide and TelehealthNovember 14, 2024 | yahoo.comTrial reveals success of telemedicine-supported, village doctor–led approach to managing atrial fibrillationSeptember 2, 2024 | msn.comExplore the Innovations of Dr. Todd H. Lanman: An Influence in Spinal NeurosurgeryAugust 27, 2024 | usatoday.comComparative Studies in Society and HistoryAugust 24, 2024 | cambridge.orgCFrom science fiction to telemedicine: the surprising 150-year history of long-range medical treatmentAugust 9, 2024 | theconversation.comTTaipei Medical University Hospital successfully advances telemedicine, leveraging technology to provide comprehensive healthcareAugust 9, 2024 | digitimes.comDNavigating telemedicine and online doctors in Louisiana for more 'consumer-centric' careAugust 4, 2024 | nola.comNTelemedicine usage can have unexpected impact on rural communities' access to local careAugust 2, 2024 | msn.comCalifornia's Telemedicine Restrictions Are Forcing Rare Disease Patients To Travel Out of State for CareMay 23, 2024 | reason.comROne reader’s view | Cowlitz County Humane Society director urges expanding telemedicine for petsMay 10, 2024 | tdn.comTSociety ManMay 2, 2024 | bloodhorse.comBAccess to remote learning, telemedicine during extreme weather events ending for millionsMay 2, 2024 | nypost.comNTelemedicine Reduces Rehospitalization, Revascularization in Post-PCI ACS PatientsApril 7, 2024 | medscape.comMTelehealth Improves Hepatitis C Treatment in Patients With Opioid Use DisorderApril 4, 2024 | medpagetoday.comMUT Southwestern, Dallas telemedicine company partner on study to improve heart health in rural communitiesApril 4, 2024 | bizjournals.comMobile pet telehealth app expands offeringsApril 1, 2024 | dvm360.comDBill allowing telemedicine for pets awaits Gov. DeSantis' signatureMarch 11, 2024 | fox13news.comFDallas Trio To Bring ‘Specialists to Patients’ With Rural Cardiac Telemedicine PilotMarch 7, 2024 | dallasinnovates.comDJournal of the Royal Asiatic SocietyFebruary 29, 2024 | cambridge.orgC(LEAD) Gov't to fully allow telemedicine services in case of doctors' collective actionFebruary 19, 2024 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTLMD, CVAC, DVAX, and CALT Company DescriptionsCalliditas Therapeutics AB (publ) NASDAQ:CALT$40.00 0.00 (0.00%) As of 08/29/2025Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.CureVac NASDAQ:CVAC$5.37 0.00 (0.00%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$5.38 +0.00 (+0.09%) As of 08/29/2025 06:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.Dynavax Technologies NASDAQ:DVAX$10.12 -0.15 (-1.46%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$10.18 +0.06 (+0.59%) As of 08/29/2025 07:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.SOC Telemed NASDAQ:TLMDSOC Telemed, Inc. provides acute care telemedicine services and technology to hospitals, health systems, physician groups, and government organizations in the United States. The company's Telemed IQ, a cloud-based software platform provides telemedicine solutions. Its telemedicine solutions include teleNeurology, telePulmonology, telePsychiatry, telecardiology, teleCritical Care (ICU), and other specialties. The company was founded in 2004 and is based in Herndon, Virginia. As of April 6, 2022, SOC Telemed, Inc. was taken private. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/25 - 08/29 Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Tencent Music Stock Outshines Spotify as China’s Music Giant Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? DICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
